SEC Company Response from Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083) (SNOA) — Jul 24, 2009
Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083)
Date: July 24, 2009 · CIK: 0001367083 · Accession: 0000950123-09-025074
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-158539
Letter
United States Securities and Exchange Commission Division of Corporation Finance Attention: Geoffrey Kruczek Re: Oculus Innovative Sciences, Inc. File No. 333-158539
Dear Mr. Kruczek:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Oculus Innovative Sciences, Inc. (the “Company”), hereby requests that the above-captioned Registration Statement on Form S-1 (the “Registration Statement”) be accelerated to July 24, 2009 at 4:30 pm EST or as soon as practicable thereafter. The Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the Company’s request is very much appreciated. Please call Amy Trombly at (617) 243-0060 if you have any questions or if we can otherwise be of assistance to you.
Very truly yours,
OCULUS INNOVATIVE SCIENCES, INC.
Show Raw Text
CORRESP
1
filename1.htm
corresp
[Company Letterhead]
July 24, 2009
VIA FACSIMILE TO (703) 813-6985 AND EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E., Mail Stop 3030
Washington, DC 20549
Attention: Geoffrey Kruczek
Re:
Oculus Innovative Sciences, Inc.
File No. 333-158539
Dear Mr. Kruczek:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as
amended, Oculus Innovative Sciences, Inc. (the “Company”), hereby requests that the above-captioned
Registration Statement on Form S-1 (the “Registration Statement”) be accelerated to July 24, 2009
at 4:30 pm EST or as soon as practicable thereafter. The Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Company
from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
•
the Company may not assert staff comments and the declaration of
effectiveness as a defense in any proceeding initiated by the Commission or
any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the Company’s request is very much appreciated. Please call
Amy Trombly at (617) 243-0060 if you have any questions or if we can otherwise be of assistance to
you.
Very truly yours,
OCULUS INNOVATIVE SCIENCES, INC.
By:
/s/
Jim Schutz
Jim Schutz
Vice President and General Counsel
cc: Amy Trombly, Esq.